BIOGEN, INC.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 40215
 
  
 
C07K PEPTIDES 18118
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 9158
 
  
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 990
 
  
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 495
 
  
 
B01D SEPARATION 2132
 
  
 
C12S PROCESSES USING ENZYMES OR MICRO-ORGANISMS TO LIBERATE, SEPARATE OR PURIFY A PRE-EXISTING COMPOUND OR COMPOSITION 25
 
  
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 2204
 
  
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 148
 
  
 
C02F TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE 154

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2012/0251,535 COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODYJun 15, 12Oct 04, 12[A61K, A61P]

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9504744 Treatment of diffuse large-cell lymphoma with anti-CD20 antibodyJun 20, 14Nov 29, 16[A61K, C07K]
9493567 Methods of treating inflammatory and autoimmune diseases with natalizumabApr 09, 10Nov 15, 16[A61K, G01N, C07K]
9296821 Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibodiesJun 15, 12Mar 29, 16[A61K, C07K, C02F]
8821873 Treatment of diffuse large-cell lymphoma with anti-CD20 antibodyOct 03, 13Sep 02, 14[A61K, C07K]
8608960 Method of purifying polypeptides by simulated moving bed chromatographyMay 21, 07Dec 17, 13[B01D]
8557244 Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibodyJul 28, 00Oct 15, 13[A61K, C07K]
8545843 Treatment of vasculitisSep 20, 10Oct 01, 13[A61K, C07K]
8329172 Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibodyAug 18, 07Dec 11, 12[A61K]
8206711 Treatment of chronic lymphocytic leukemia using anti-CD20 antibodiesDec 02, 09Jun 26, 12[A61K]
8168190 HBV core antigen particles with multiple immunogenic components attached via peptide ligandsJan 24, 06May 01, 12[A61K, C07K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2014/0363,424 USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANTAbandonedJan 14, 14Dec 11, 14[C07K]
2014/0056,887 COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODYAbandonedNov 01, 13Feb 27, 14[A61K]
2013/0331,554 ENRICHMENT AND CONCENTRATION OF SELECT PRODUCT ISOFORMS BY OVERLOADED BIND AND ELUTE CHROMATOGRAPHYAbandonedNov 15, 11Dec 12, 13[C07K]
2013/0273,039 COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODYAbandonedApr 23, 13Oct 17, 13[A61K]
2011/0177,093 USE OF BCMA AS AN IMMUNOREGULATORY AGENTAbandonedAug 24, 10Jul 21, 11[A61K, A61P]
2011/0165,159 USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANTAbandonedMar 18, 11Jul 07, 11[A61K, A61P]
2009/0238,762 Method for treating joint damageAbandonedNov 14, 06Sep 24, 09[A61K]
7510712 Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodiesExpiredAug 17, 07Mar 31, 09[A61K, C07K]
7510713 Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodiesExpiredAug 17, 07Mar 31, 09[A61K, C07K]
2009/0074,760 USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANTAbandonedApr 09, 08Mar 19, 09[A61K, A61P]
7501264 Methods of producing 7C10 and 16C10 CD80-specific antibodiesExpiredAug 17, 07Mar 10, 09[C12N]
2009/0054,632 Hydrophobically-modified protein compositions and methodsAbandonedAug 20, 07Feb 26, 09[C07K]
7491393 Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodiesExpiredAug 17, 07Feb 17, 09[A61K, C07K]
7429644 Humanized anti-LT-.beta.-R antibodiesExpiredApr 10, 03Sep 30, 08[C12P]
7422739 Anti-CD20 antibodiesExpiredJul 25, 01Sep 09, 08[A61K]
7417128 7C10 and 16C10 CD80-specific antibodiesExpiredOct 26, 06Aug 26, 08[C07K]
2007/0031,920 High expression locus vector based on ferritin heavy chain gene locusAbandonedOct 22, 03Feb 08, 07[C07H, C12P, C12N, C07K]
7173046 CD40:CD154 binding interrupter compounds and use thereof to treat immunological complicationsExpiredFeb 28, 03Feb 06, 07[A61K]
2006/0172,346 Methods of designing and producing novel compounds having improved binding affinity for CD154 or other trimeric proteinsAbandonedDec 23, 05Aug 03, 06[G01N, C07K]
2006/0166,866 Cell adhesion inhibitorsAbandonedOct 07, 03Jul 27, 06[A61K, C07K]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.